General Information of Drug (ID: DMKE7FG)

Drug Name
1-(pyridin-2-yl)piperazine Drug Info
Synonyms 1-Pyridin-2-yl-piperazine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
94459
CAS Number
CAS 34803-66-2
TTD Drug ID
DMKE7FG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [3]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [4]
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [5]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [6]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [7]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [8]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [9]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [10]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [11]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Phospholipase D1 (PLD1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US9127005, P2C DMMT98V N. A. N. A. Patented [13]
US9453017, 1 DMVQ3IX N. A. N. A. Patented [14]
US9127005, P2B DM3R7BT N. A. N. A. Patented [13]
ML272 DMNEY58 N. A. N. A. Patented [14]
US9127005, P0L DMKLYCV N. A. N. A. Patented [13]
US9453017, 2 DMPH05Y N. A. N. A. Patented [14]
HALOPEMIDE DMF6V8W Discovery agent N.A. Investigative [15]
1-(pyridin-4-yl)piperazine DM78AJ1 Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 8 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [4]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [8]
AGN-199981 DMP5Y1A Neuropathic pain 8E43.0 Phase 2 [16]
INDORAMIN DMNSJFD Hypertension BA00-BA04 Withdrawn from market [17]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [10]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [12]
A-80426 DMBC3DG N. A. N. A. Terminated [18]
WB-4101 DMQU8B1 N. A. N. A. Terminated [19]
SK&F-104078 DMRADBU N. A. N. A. Terminated [17]
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [20]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxazosin DM9PLRH Benign prostatic hyperplasia GA90 Approved [21]
Armodafinil DMGB035 Malignant glioma 2A00.0 Approved [22]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [23]
Moxisylyte DMFCLYW Erectile dysfunction HA01.1 Approved [24]
Terazosin DM3JCVS Benign prostatic hyperplasia GA90 Approved [25]
Bunazosin DM4I8O7 Glaucoma/ocular hypertension 9C61 Approved [26]
Trimazosin DM1QLST Congestive heart failure BD10 Approved [27]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [8]
DL-017 DMM8GZT Hypertension BA00-BA04 Phase 1 [28]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [29]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [30]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [30]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [31]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [32]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [33]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [34]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [8]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [29]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [29]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [35]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2B (ADRA2B) TTWM4TY ADA2B_HUMAN Inhibitor [1]
Phospholipase D1 (PLD1) TT3T17P PLD1_HUMAN Inhibitor [2]

References

1 Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
2 Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privil... Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
5 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
6 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
7 Clinical pipeline report, company report or official report of Klus Pharma
8 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
11 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
12 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
13 Isoform selective phospholipase D inhibitors. US9127005.
14 Antiviral therapies with phospholipase D inhibitors. US9453017.
15 Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.
16 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
17 Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
18 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
19 alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
20 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
21 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
22 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
23 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
24 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
25 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
26 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
27 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
28 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
29 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
30 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
32 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
33 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
34 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
35 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.